Zoetis Inc. $ZTS Stock Holdings Lowered by Parr Mcknight Wealth Management Group LLC

Posted by Alanna Baker on Jun 1st, 2026

Parr Mcknight Wealth Management Group LLC lowered its position in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 54.2% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 8,509 shares of the company’s stock after selling 10,051 shares during the period. Parr Mcknight Wealth Management Group LLC’s holdings in Zoetis were worth $1,071,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of ZTS. Norges Bank bought a new position in Zoetis in the 4th quarter valued at about $734,425,000. Vanguard Group Inc. boosted its stake in shares of Zoetis by 12.9% during the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares in the last quarter. Diamond Hill Capital Management Inc. acquired a new position in shares of Zoetis in the 3rd quarter valued at $394,010,000. Nordea Investment Management AB boosted its position in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the period. Finally, Montrusco Bolton Investments Inc. boosted its holdings in shares of Zoetis by 256.7% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company’s stock worth $266,888,000 after buying an additional 1,560,314 shares during the period. Institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, Director Michael B. Mccallister acquired 3,000 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares in the company, valued at approximately $1,906,986.24. This represents a 13.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average cost of $75.39 per share, with a total value of $501,343.50. Following the completion of the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders bought 11,650 shares of company stock valued at $886,384. Corporate insiders own 0.22% of the company’s stock.

Zoetis Trading Up 0.2%

Shares of ZTS stock opened at $77.81 on Monday. Zoetis Inc. has a 52-week low of $72.38 and a 52-week high of $172.23. The stock has a market cap of $32.62 billion, a price-to-earnings ratio of 12.90, a P/E/G ratio of 1.27 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm has a fifty day moving average of $104.29 and a 200-day moving average of $117.01.

Zoetis (NYSE:ZTS – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same period last year, the company earned $1.48 EPS. The business’s revenue for the quarter was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.89 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 2.7%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

Wall Street Analyst Weigh In

A number of brokerages have commented on ZTS. Citigroup decreased their price objective on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. Leerink Partners restated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Bank of America upped their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a report on Friday, February 13th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $133.92.

Check Out Our Latest Stock Analysis on ZTS

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

Positive Sentiment: Zoetis presented at the Stifel Jaws & Paws Conference, which may have helped keep some investor attention on the company’s long-term animal health growth story. Zoetis Inc. (ZTS) Presents at Stifel Jaws & Paws Conference 2026 Transcript
Neutral Sentiment: Brokerage coverage now shows a consensus “Hold” rating on Zoetis, suggesting analysts see limited near-term upside or downside from current levels. Zoetis Inc. (NYSE:ZTS) Receives Consensus Rating of “Hold” from Brokerages
Negative Sentiment: Argus Research downgraded Zoetis, adding to concerns that Wall Street’s view on the stock is softening. Argus Research downgrades Zoetis (ZTS)
Negative Sentiment: Multiple law firms announced or promoted a securities class action tied to Zoetis, which can weigh on sentiment because it raises legal and reputational risk for the company. ZTS INVESTOR ALERT: Zoetis Inc. Investors with Substantial Losses Have Opportunity to Lead the Zoetis Class Action Lawsuit

Zoetis Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.